Compare
Atara Biotherapeutics, Inc. vs Agenus Inc vs ImmunityBio, Inc. vs Beam Therapeutics Inc.
| Latest fiscal year | Atara Biotherapeutics, Inc. ATRA | Agenus Inc AGEN | ImmunityBio, Inc. IBRX | Beam Therapeutics Inc. BEAM |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $120.77M | $114.20M | $113.29M | $139.74M |
| Revenue growth (YoY) | -6.3% | +10.4% | +668.3% | +120.0% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | 29.7% | -17.7% | -226.0% | -274.6% |
| Net margin | 27.1% | -2.7% | -310.2% | -57.2% |
| Net income | $32.69M | -$3.08M | -$351.40M | -$79.99M |
| EPS (Diluted) | $2.57 | $0.00 | -$0.38 | -$0.81 |
| Operating cash flow | -$50.94M | -$77.19M | -$304.94M | -$345.10M |
| Free cash flow | -$50.94M | -$77.20M | -$308.78M | -$360.05M |
| Cash & equivalents | $8.48M | $3.00M | $88.33M | $294.94M |
| Total assets | $20.23M | $226.80M | $501.90M | $1.48B |
| Total liabilities | $58.74M | n/a | $1.00B | $242.82M |
| Shareholders' equity | -$38.50M | -$271.11M | -$500.47M | $1.24B |
| Return on year-end equity | n/a | n/a | n/a | -6.5% |
| Shares outstanding | 7.32M | 35.32M | 1.01B | 101.75M |
Revenue, most recent five fiscal years
| Fiscal year | Atara Biotherapeutics, Inc. | Agenus Inc | ImmunityBio, Inc. | Beam Therapeutics Inc. |
|---|---|---|---|---|
| Latest | $120.77M Ended 2025-12-31 | $114.20M Ended 2025-12-31 | $113.29M Ended 2025-12-31 | $139.74M Ended 2025-12-31 |
| 1 year earlier | $128.94M Ended 2024-12-31 | $103.46M Ended 2024-12-31 | $14.74M Ended 2024-12-31 | $63.52M Ended 2024-12-31 |
| 2 years earlier | $8.57M Ended 2023-12-31 | $156.31M Ended 2023-12-31 | $622.0K Ended 2023-12-31 | $377.71M Ended 2023-12-31 |
| 3 years earlier | $63.57M Ended 2022-12-31 | $98.02M Ended 2022-12-31 | $240.0K Ended 2022-12-31 | $60.92M Ended 2022-12-31 |
| 4 years earlier | n/a | $295.67M Ended 2021-12-31 | $934.0K Ended 2021-12-31 | $51.84M Ended 2021-12-31 |